retatrutide farts Eli Lilly infiltrates anti-obesity market as Phase III trial for begins How Bad Are Retatrutide Side

All diabetes medications in this class carry a similar, higher risk

P.RmerJ.HistologyJ

Below is an overview of how the two compare: Mechanism of Action: Retatrutide: Triple agonist (GLP-1, GIP, glucagon) Zepbound: Dual agonist (GLP-1, GIP) Developer: Retatrutide: Eli Lilly and Company (investigational) Zepbound: Eli Lilly and Company (approved) Regulatory Status: Retatrutide: Phase III clinical development Zepbound: FDA-approved for obesity, obstructive sleep apnea Weight Loss Efficacy: Retatrutide: Up to ~28.7% (68 weeks

Rapid hepatic metabolism blunts the endocrine action of portally infused GLP-1

(PubMed) Bernhard W, Shunova A, Machann J, et al